Dopamine’s effects in the brain are mediated by postsynaptic D1 and D2 receptors. Adenosine A1 and A2A receptors are uniquely positioned to counteract the excessive stimulation of dopamine receptors ...

Hopes for this approach have now received a boost from a study by Van Kampen and Eckman, showing that activation of a particular dopamine receptor subtype stimulates neurogenesis and functional ...

The drug is a partial agonist that selectively targets dopamine D1/D5 receptor subtypes. Also in phase 2, the company has CVL-871 for dementia-related apathy and also has Fast Track status.